Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAVA-1207 in refractory metastatic castration-resistant prostate cancer
2024-515821-27-00Phase 2Completed
- Sponsor
- LAVA Therapeutics
- Start
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 2, open-label trial of LAVA-1207, pembrolizumab and aldesleukin in prostate cancer (PCa) (3 arms), sponsored by LAVA Therapeutics. Primary endpoints: Safety and tolerability in Part 1, Dose-limiting toxicities in Part 1 and 1 more. Started Aug 2024; status: completed.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2024-515821-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515821-27-00.